Regeneron Pharmaceuticals Inc. (REGN)
Россия
  • Россия
  • Украина

Regeneron Pharmaceuticals Inc. (REGN)

Contact Details

777 Old Saw Mill River Rd # 10, Tarrytown, New York, USA 10591-6707
(914) 847-7000
777 Old Saw Mill River Rd # 10, Tarrytown, New York, USA 10591-6707

General Information

Regeneron Pharmaceuticals Inc. is a biopharmaceutical company that discovers, develops, and intends to commercialize therapeutic drugs for the treatment of serious medical conditions. Regeneron`s platform technologies include Targeted GenomicsTM, FunctionomicsTM, and Designer Protein TherapeuticsTM. Regeneron has drugs in clinical and preclinical development for the potential treatment of obesity, rheumatoid arthritis, cancer, allergies, asthma, amyotrophic lateral sclerosis, constipating conditions, ischemia, and other diseases and disorders. (PRESS RELEASE)

Contact Information

Phone(914) 847-7000
Customer Service Phone(888) 825-5249
Fax(914) 345-7544
Website 1http://www.regeneron.com
LinkedInLinkedIn
Twitter@regeneron
Thomson Reuters PermID4295907752

Executives

NamePositionTotal Annual CompensationYearPercent Change in Compensation
Dr. Leonard S. Schleifer,M.D.,PhDCEO and President$41,965,424201415.7%
Robert J. TerifayDivisional Senior VP$8,396,32720149.3%
Robert E. LandryCFO and Divisional Senior VP$7,322,9562014-41.9%
Dr. George D. Yancopoulos,M.D.,PhDChief Scientific Officer and Divisional President$35,506,811201414.5%
Dr. Neil Stahl,PhDDivisional Executive VP$16,254,115201413.2%

Government Contracts

Largest Contracts

AgencyProduct or ServiceSigned DateObligation Amount
Department of Veterans AffairsDrugs and BiologicalsOctober 09, 2008$14,130.70
Department of Veterans AffairsDrugs and BiologicalsSeptember 18, 2008$0
Department of Veterans AffairsDrugs and BiologicalsJune 22, 2015$0

Corporate Data

Industries

  • Pharmaceutical Preparation Manufacturing

SIC Industries

  • Pharmaceutical Preparations

Company Size

Sales Volume$4.1 billion
Employees4,300

Ownership

Ticker SymbolREGN
ExchangeNASDAQ Global Select Market
Type of EntityFor Profit Organization
Type of OwnershipNot Tax Exempt Corporate Entity
Federal AwardsReceives Contracts
Other CategorizationsManufacturer of Goods
State of IncorporationNew York
Year Founded1988

Stocks

Previous Close404.94
Open407.37
Bid395.86 x 100
Ask396.14 x 2,900
Day`s Range392.92 - 407.37
52-Week Range359.68 - 592.4
Average Volume (1M)1,025,495
Forward P/E64.51x
Trailing P/E48.21x
Beta1.04x
Market Cap.$42,432.9 Million
Last Dividend Amount0
1y Target Price Est.615.29

Financials

Period EndingDec. 31, 2015Sep. 30, 2015Jun. 30, 2015Mar. 31, 2015
Total Revenue1,098,0771,137,422998,617869,612
Cost of Revenue110,831109,08388,84083,955
Gross Profit987,246.21,028,339909,777785,657
Research Development461,210.1425,924390,330343,113
Selling General and Administrative294,954209,993174,588158,991
Depreciation and Amortization----
Other Operating Expenses(0.1)---
Total Operating Expenses866,995745,000653,758586,059
Other Income/Expenses Net(0.2)---
Earnings Before Interest and Taxes231,082392,422344,859283,553
Interest Expense3,6091,7152,7486,169
Income Before Tax227,289393,289327,996276,523
Income Tax Expense72,295182,891133,353200,502
Minority Interest----
Net Income from Continuing Ops154,994210,398194,64376,021
Discontinued Operations----
Extraordinary Items----
Effect of Accounting Changes----
Other Items----
Net Income154,994210,398194,64376,021
Preferred Stock and Other Adjustments----
Net Income Applicable to Common Shares154,994210,398194,64376,021